Skip to main content
SpringerLink
Log in

Thrombocytopenia during heparin therapy: a clinical conundrum

  • Practice Point
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Warkentin TE et al. (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108: 2937–2941

    Article  CAS  Google Scholar 

  2. Greinacher A et al. (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5: 1666–1673

    Article  CAS  Google Scholar 

  3. Lo GK et al. (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4: 759–765

    Article  CAS  Google Scholar 

  4. Greinacher A et al. (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 94: 132–135

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. The Zena and Michael A Wiener Cardiovascular Institute and The Marie Josée and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA jonathan.halperin@mssm.edu

Authors and Affiliations

  1. JL Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Mount Sinai School of Medicine, and Director of Clinical Cardiology Services in the Zena and Michael A Wiener Cardiovascular Institute at Mount Sinai Medical Center, New York, NY, USA.,

    Jonathan L Halperin

Authors
  1. Jonathan L Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

JL Halperin has received consultancy fees from Astellas Pharma, Bayer Healthcare, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson and Sanofi-Aventis for advisory activities involving the development of new anticoagulant drugs, none of which are currently approved for clinical use in any indication.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halperin, J. Thrombocytopenia during heparin therapy: a clinical conundrum. Nat Rev Cardiol 5, 440–441 (2008). https://doi.org/10.1038/ncpcardio1254

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1254

  • Springer Nature Limited

Search

Navigation